Factor XI Antisense Modulation for Predictable Anticoagulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulant agents lack predictability and specificity, leading to adverse side effects such as bleeding complications and heparin-induced thrombocytopenia, and there are no anticoagulants that target only the intrinsic or extrinsic coagulation pathway effectively.
Innovation Solution
Development of methods, compounds, and compositions that modulate the expression of Factor 11 mRNA and protein using specific inhibitors, such as nucleic acids, proteins, or small molecules, to reduce thromboembolic complications by targeting the coagulation cascade.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anticoagulant agents (warfarin, heparin, LMWH) are used to treat thromboembolic complications, then anticoagulant effect is achieved, but predictability and specificity are insufficient leading to adverse side effects
Solution Approach 1:
The patent segments the coagulation cascade into distinct pathways (intrinsic and extrinsic) and targets Factor XI specifically within the intrinsic pathway. This segmentation allows for pathway-specific inhibition without affecting other coagulation factors, thereby improving predictability and reducing off-target adverse effects compared to broad-spectrum anticoagulants like warfarin and heparin.
Solution Approach 2:
The patent employs Factor XI as an intermediary target in the coagulation cascade. By inhibiting Factor XI, the therapy indirectly prevents activation of downstream factors (IX, X, and ultimately thrombin) without directly blocking thrombin or factor Xa. This intermediary approach provides more specific control over the coagulation process, improving predictability while reducing adverse side effects.
2Reliability
If current anticoagulant agents are used to prevent thrombosis, then thromboembolic complications are treated, but specificity is insufficient affecting multiple coagulation pathways
Solution Approach 1:
The patent divides the coagulation system into separable pathways and selectively targets the intrinsic pathway through Factor XI inhibition. This segmentation enables specific action on one pathway without interfering with the extrinsic pathway, achieving the desired specificity that current anticoagulants cannot provide.
Solution Approach 2:
Instead of inhibiting downstream factors (thrombin, factor Xa) that converge both pathways, the patent inverts the approach by targeting Factor XI upstream in the intrinsic pathway only. This inverted strategy achieves pathway-specific inhibition by working backwards from the convergence point, allowing selective extrinsic pathway preservation.
Data Source
AI summary
Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.